Pampfer Serge

Pampfer Serge Email and Phone Number

Chief Executive Officer @ MAEDIA Consulting
Belgium
Pampfer Serge's Location
Belgium, Belgium
Pampfer Serge's Contact Details

Pampfer Serge work email

Pampfer Serge personal email

n/a
About Pampfer Serge

THE HEDGEHOG AND THE FOXOnce upon a time, there was a fox who wanted to catch a hedgehog and make him his feast. The fox, already sure of his success, boasted he knew a thousand tricks to catch his prey. Meanwhile, the hedgehog had just one single strategy for journeying through the woods and fields to reach his destination : Everytime the fox approached, he would roll into a tight ball of spines and then wait until the fox grew tired of not being able to get hold of him. Then, the hedgehog would simply continue his route without deviating from it.Night after night, the fox used up all his thousand tricks, one by one. He used his paws, his teeth, even a piece of wood ... No matter how, he never managed to grab the hedgehog ! In the end, starving to death after all these unsuccesful attempts, the fox had to give up his gruesome plan. The hedgehog, in contrast, reached the final objective he had set to himself without trouble and on time. __________________________________________________________________________________Freely adapted from an ancient tale compiled by Erasmus circa 1500 ("multa novit vulpes verum echinus unum magnum"). Serge boyscout totem name was ... Hedgehog.

Pampfer Serge's Current Company Details
MAEDIA Consulting

Maedia Consulting

View
Chief Executive Officer
Belgium
Website:
maedia.com
Employees:
1
Pampfer Serge Work Experience Details
  • Maedia Consulting
    Chief Executive Officer
    Maedia Consulting
    Belgium
  • Lovaltech
    Chief Executive Officer
    Lovaltech Oct 2023 - Present
    LovalTech is a start-up company dedicated to developing nasal vaccines against infectious diseases. Nasal vaccine administration triggers a mucosal immune response that blocks contagiousness and prevents transmission, on top of the classical immune response activated by the intra-muscular route. The first vaccine candidate developed by Lovaltech is ready for entering phase I/IIa clinical trials in 2024.
  • Maedia Consulting
    Chief Executive Officer
    Maedia Consulting Jan 2010 - Present
    MAEDIA srl combines activities in corporate management and in book publishing since 2010. Consulting activities include C-Level and Board-level duties in the life sciences industry while publishing activities comprise "in conversation with" interviews and other interactions with artists. In both endeavors, the focus of MAEDIA is on transversal value creation and community sharing.
  • Eurekare
    Chief Scientific Officer
    Eurekare Mar 2021 - Aug 2023
    EureKARE is an international investment company focused on the creation and expansion of companies active in either microbiome or synthetic biology in Europe. EureKARE has established two biotech studios, one in Paris and one in Brussels, to stimulate the emergence of new technologies and applications in these two markets, both of them being driven by impressive 25% annual growth rates. EureKARE also develops an AI-powered tool to identify the most promising scientists and institutions doing research in microbiome and synthetic biology in order to secure premium access to the best science and innovation Europe is producing in these fields. In terms of investment capacity, EureKARE has already raised around € 50 million to be engaged in both new startups and maturing companies in 2021-2022.
  • Wbc Ventures
    Managing Director
    Wbc Ventures Jan 2019 - Dec 2020
    Liege, Liège, Be
    WBC Ventures is the new iteration of our original company (Biotech Coaching SA). After 12 years operating as a successful incubator and seed investor for 60+ life science companies, we have transitioned to an accelerator and consulting business model in early 2019. Around our new core Market Access Accelerator Program and leveraging our long and proven experience in the life science (biotech, medtech, healthtech and agri-foodtech) sector, we have assembled a tight network of experts, mentors, financial and industrial partners and alumni to help scaling-up companies meet their global objectives and achieve maximal societal and commercial impact. WBC Ventures also offers screening and scouting services to investors looking for qualified investment proposals and to companies looking for acquisition or licensing opprotunities.
  • Wbc Ventures
    Managing Director
    Wbc Ventures Sep 2006 - Dec 2018
    Liege, Liège, Be
    WBC Incubator (Biotech Coaching SA) was launched by the Region of Wallonia in 2006 to stimulate the creation and expansion of life science spin-offs, start-ups and spin-outs in the French-speaking part of Belgium. Over the past years, WBC has contributed to the creation of 60 new companies whose innovative applications range from cell therapy to water bioremediation to neuromodulation devices. WBC also supports more mature companies during their industrial and commercial phases. WBC invests about 1.5 M€ in its portfolio companies every year and is currently a shareholder and board observer in several of them.
  • Peace Of Meat
    (Interim) Chief Scientific Officer
    Peace Of Meat Nov 2019 - Dec 2019
    Antwerpen, Be
    Peace of Meat is the first Cultivated Meat pure player to be launched in Belgium. Based on a unique strategy focusing on building premium development and manufacturing consortia around the world, Peace of Meat aims to deliver exceptional cultivated / clean / cultured / cell-based / lab-grown / in vitro / you-name-it / meat products to the food market.
  • Beta-Cell Nv
    Chief Operating Officer
    Beta-Cell Nv 2002 - 2006
    Beta-Cell NV was created as a spin-off company to develop novel cell therapies for type I diabetes. Its first preclinical program involved the use of fetal pig pancreatic cells and their study for graft survival, functionality and safety in non-human primates. The company also diversified its product pipeline through the design and validation of an innovative screening platform that was proposed to the biopharmaceutical industry to identify new drug candidates for diabetes.
  • Arevia Gmbh
    Chief Scientific Officer
    Arevia Gmbh 2000 - 2002
    Arevia GmbH was created as a start-up company to discover and validate new biomarkers and potential drug targets for endometriosis. Its innovative screening platform led to the identification of several new genes and proteins that were functionally linked to the disease occurence and progression. Arevia GmbH was acquired by Schering (now Bayer Pharma) AG.
  • Ucl Human Reproduction Research Unit
    Director (Maître De Recherche Fnrs)
    Ucl Human Reproduction Research Unit 1991 - 2000
    One of the research programs pursued in the Human Reproduction Research Unit of the University of Louvain School of Medecine was aimed at a better understanding of the cellular and molecular regulation of murine and human embryos during the preimplantation phase of pregnancy. This program led to major findings in the mechanisms of cellular apoptosis, stem cell differentiation and cytokine interactions as well as about the impact of maternal diabetes on early embryonic development.

Pampfer Serge Skills

Biotechnology Start Ups Technology Transfer Lifesciences R&d Life Sciences Molecular Biology Pharmaceutical Industry Biopharmaceuticals Entrepreneurship Biochemistry Immunology Science Medical Devices Clinical Development Oncology Drug Discovery Commercialization Genomics Research And Development

Pampfer Serge Education Details

  • Albert Einstein College Of Medicine
    Albert Einstein College Of Medicine
    Molecular Biology
  • Université Catholique De Louvain
    Université Catholique De Louvain
    Cellular Biology

Frequently Asked Questions about Pampfer Serge

What company does Pampfer Serge work for?

Pampfer Serge works for Maedia Consulting

What is Pampfer Serge's role at the current company?

Pampfer Serge's current role is Chief Executive Officer.

What is Pampfer Serge's email address?

Pampfer Serge's email address is pa****@****ing.com

What schools did Pampfer Serge attend?

Pampfer Serge attended Albert Einstein College Of Medicine, Université Catholique De Louvain.

What skills is Pampfer Serge known for?

Pampfer Serge has skills like Biotechnology, Start Ups, Technology Transfer, Lifesciences, R&d, Life Sciences, Molecular Biology, Pharmaceutical Industry, Biopharmaceuticals, Entrepreneurship, Biochemistry, Immunology.

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant

Download 750 million emails and 100 million phone numbers

Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.